The demand for AI servers and high-performance computing (HPC) is causing shortages of raw materials and price pressures in the supply chain of printed circuit boards (PCBs) and IC substrates in Taiwan. CCL prices have increased by approximately 20-30% in the first half of the year, and this trend may continue from the second half of 2026 to 2027. The supply shortage rate for second-generation low-dielectric glass fiber cloth exceeds 60%, and the shortage of T-Glass is also expanding. High-spec substrates for AI servers have higher CCL specifications and usage than consumer electronics, meaning changes in raw material prices have a greater impact on manufacturing costs. CCL is a fundamental material for circuit boards, and PP is used when bonding multiple substrate layers. Despite the increase in demand for high-spec PCBs, it is difficult to immediately increase the supply of materials. Taiwan's Zhen Ding has reflected CCL costs in product prices, while Jingfeng has passed on 70-80% of the cost burden to customers. Dingying Holdings reported a gross profit margin of 14.02% in the second quarter, and Yao Hua has completed price increase negotiations. In the IC substrate sector, companies such as Xinxing, Jingshuo, and Nanya have been mentioned, with the packaging demand for AI GPUs and ASICs increasing the demand for high-spec IC substrates. This issue demonstrates that the expansion of AI infrastructure is exerting cost pressures on raw materials, substrates, and equipment.
This content is provided for general informational purposes only and doesn't constitute financial, investment, legal, or tax advice. Any events, rewards, online promotions, or related information mentioned herein should not be considered a recommendation, solicitation, or invitation to purchase, sell, trade, or otherwise deal in any crypto assets. Crypto assets are highly volatile and may result in loss. The availability of WEEX services, products, and related events may vary by region. You are responsible for ensuring that your participation is in accordance with applicable local laws and regulations.






Moderna shares more than doubled on 19 August 2026 after Merck and Moderna said the Phase 3 INTerpath-001 trial of intismeran autogene plus KEYTRUDA met its recurrence-free survival endpoint in resected melanoma. This page explains what the result is, why the stock reacted this hard, what is still unknown, which dates come next (presentation and earnings, both unconfirmed), and what a trader can actually do on WEEX — which does not list Moderna; the nearest instrument is the XBI-USDT biotech ETF perpetual. No price targets, no forecasts.















Long-end U.S. Treasury yields surged to multi-year highs, pressuring technology, semiconductor, storage, and optical communication stocks and driving a clear cooling in market risk appetite. At the same time, Anthropic’s revenue came in below some bullish expectations, prompting investors to reassess the AI growth narrative; Unitree Robotics officially listed on the STAR Market, extending momentum in robotics and embodied AI; while SpaceX and other commercial space names showed relative resilience. Investors are now focused on tonight’s Federal Reserve minutes for clearer signals on the policy path and broader market sentiment.









Moderna shares more than doubled on 19 August 2026 after Merck and Moderna said the Phase 3 INTerpath-001 trial of intismeran autogene plus KEYTRUDA met its recurrence-free survival endpoint in resected melanoma. This page explains what the result is, why the stock reacted this hard, what is still unknown, which dates come next (presentation and earnings, both unconfirmed), and what a trader can actually do on WEEX — which does not list Moderna; the nearest instrument is the XBI-USDT biotech ETF perpetual. No price targets, no forecasts.